# Avalo Therapeutics, Inc.: overview AVTX · Nasdaq · CIK 1534120 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/avtx.md) · [Financials](/companies/avtx/financials.md) · [Filings](/companies/avtx/filings.md) · [Insiders](/companies/avtx/insiders.md) Latest reported revenue: [$59.0k](/filings/0001534120-26-000011.md) for Q4 FY2025, three months to 2025-12-31, from the 10-K filed Mar 23, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001534120-26-000011). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [249](/filings/0001534120-25-000018.md) | [192 d](/filings/0001534120-26-000011.md) | not reported | not reported | [0.0](/filings/0001534120-25-000018.md) | [59.0 d](/filings/0001534120-26-000011.md) | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(5165.1%)](/filings/0001534120-25-000018.md) | [(6932.8%) d](/filings/0001534120-26-000011.md) | not reported | not reported | not reported | [(33461.0%) d](/filings/0001534120-26-000011.md) | not reported | not reported | | Net margin | % | [9251.8%](/filings/0001534120-25-000018.md) | [(18405.7%) d](/filings/0001534120-26-000011.md) | not reported | not reported | not reported | [(23254.2%) d](/filings/0001534120-26-000011.md) | not reported | not reported | | Diluted EPS | $ per share | [(2.83)](/filings/0001534120-25-000018.md) | not reported | [(1.25)](/filings/0001534120-26-000033.md) | [(1.92)](/filings/0001534120-26-000049.md) | [(2.19)](/filings/0001534120-25-000018.md) | not reported | [(0.98)](/filings/0001534120-26-000033.md) | [(0.83)](/filings/0001534120-26-000049.md) | | Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [5.4](/filings/0001628280-23-009630.md) | [18.1](/filings/0001628280-24-013786.md) | [1.9](/filings/0001628280-25-013986.md) | [0.4](/filings/0001534120-26-000011.md) | [0.1](/filings/0001534120-26-000011.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(1521.6%)](/filings/0001628280-23-009630.md) | [(207.4%)](/filings/0001628280-24-013786.md) | [(1421.6%)](/filings/0001628280-25-013986.md) | [(15535.6%)](/filings/0001534120-26-000011.md) | [(123601.7%)](/filings/0001534120-26-000011.md) | | Net margin | % | [(1563.1%)](/filings/0001628280-23-009630.md) | [(230.8%)](/filings/0001628280-24-013786.md) | [(1639.5%)](/filings/0001628280-25-013986.md) | [(7965.8%)](/filings/0001534120-26-000011.md) | [(132642.4%)](/filings/0001534120-26-000011.md) | | Diluted EPS | $ per share | not reported | [(1063.00)](/filings/0001628280-24-013786.md) | [(113.58)](/filings/0001628280-25-013986.md) | [(20.91)](/filings/0001534120-26-000011.md) | [(5.84)](/filings/0001534120-26-000011.md) | | Free cash flow | $m | [(71.0)](/filings/0001628280-23-009630.md) | [(26.8)](/filings/0001628280-24-013786.md) | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/avtx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $94.3m | 5,100,216 | | Added +2,220,735 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $80.7m | 4,365,553 | | Added +4,038,471 | | [Deep Track Capital, LP](/funds/1856083.md) | 2026-06-30 | $66.7m | 3,610,000 | | New +3,610,000 | | [Caligan Partners LP](/funds/1727492.md) | 2026-06-30 | $58.5m | 3,163,866 | | Added +1,528,843 | | [TCG Crossover Management, LLC](/funds/1839948.md) | 2026-06-30 | $55.8m | 3,017,120 | | Added +2,278,737 | | [Affinity Asset Advisors, LLC](/funds/1773195.md) | 2026-06-30 | $53.6m | 2,900,000 | | Added +1,559,160 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $53.4m | 2,889,287 | | Added +2,817,633 | | [FARALLON CAPITAL MANAGEMENT, L.L.C.](/funds/909661.md) | 2026-06-30 | $46.2m | 2,498,000 | | Added +1,582,000 | | [Point72 Asset Management, L.P.](/funds/1603466.md) | 2026-06-30 | $44.1m | 2,387,026 | | Added +1,470,884 | | [Avoro Capital Advisors LLC](/funds/1633313.md) | 2026-06-30 | $43.1m | 2,333,333 | | Added +923,333 | ## Recent filings [All 1,209 filings](/companies/avtx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-06 | 07:03 ET | [10-Q](/filings/0001534120-26-000049.md) | Quarterly report, period 2026-06-30 | 0001534120-26-000049 | | 2026-08-06 | 07:01 ET | [8-K](/filings/0001534120-26-000048.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001534120-26-000048 | | 2026-06-23 | 07:01 ET | [8-K](/filings/0001534120-26-000044.md) | 5.02 Departure or appointment of officers or directors | 0001534120-26-000044 | | 2026-06-16 | 07:18 ET | [8-K](/filings/0001534120-26-000042.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001534120-26-000042 | | 2026-06-12 | 16:06 ET | [8-K](/filings/0001534120-26-000040.md) | 3.02 Unregistered sale of equity; 3.03 Change to security holders’ rights; 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001534120-26-000040 | | 2026-06-08 | 16:19 ET | [8-K](/filings/0001534120-26-000036.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001534120-26-000036 | | 2026-05-13 | 07:02 ET | [10-Q](/filings/0001534120-26-000033.md) | Quarterly report, period 2026-03-31 | 0001534120-26-000033 | | 2026-05-13 | 07:00 ET | [8-K](/filings/0001534120-26-000032.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001534120-26-000032 | | 2026-05-07 | 19:38 ET | [8-K](/filings/0001104659-26-056482.md) | 1.01 Entry into a material agreement; 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-056482 | | 2026-05-05 | 16:01 ET | [8-K](/filings/0001534120-26-000028.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001534120-26-000028 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001534120-26-000011.md), filed Mar 23, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1534120 - Tickers: AVTX - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 16:18 ET. No prices; not investment advice.